financetom
Business
financetom
/
Business
/
Voya Financial Q3 Adjusted Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Voya Financial Q3 Adjusted Earnings, Revenue Rise
Nov 4, 2024 2:42 PM

05:18 PM EST, 11/04/2024 (MT Newswires) -- Voya Financial ( VOYA ) reported Q3 adjusted operating earnings late Monday of $1.90 per diluted share, up from $1.74 a year earlier.

Analysts surveyed by Capital IQ expected normalized EPS of $2.04.

Revenue for the quarter ended Sept. 30 was $1.96 billion, up from $1.82 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.86 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
New York Times Insider Sold Shares Worth $253,283, According to a Recent SEC Filing
New York Times Insider Sold Shares Worth $253,283, According to a Recent SEC Filing
May 23, 2024
05:32 PM EDT, 05/23/2024 (MT Newswires) -- R Anthony Benten, Senior Vice President, Treasurer & Chief Accounting Officer, on May 21, 2024, sold 5,171 shares in New York Times ( NYT ) for $253,283. Following the Form 4 filing with the SEC, Benten has control over a total of 38,576 shares of the company, with 38,576 shares held directly. SEC...
FTX bankruptcy lawyers were not complicit in fraud, report finds
FTX bankruptcy lawyers were not complicit in fraud, report finds
May 23, 2024
NEW YORK (Reuters) - FTX's bankruptcy lawyers at Sullivan & Cromwell were not complicit in the fraud that caused the crypto company to collapse, a court-appointed examiner concluded on Thursday. Former FTX CEO Sam Bankman-Fried was convicted in November of stealing $8 billion from FTX customers. FTX creditors and investors had accused the company's lawyers at Sullivan & Cromwell of...
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer
May 23, 2024
05:32 PM EDT, 05/23/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said late Thursday that combination therapy of GN7075 and Libtayo, or cemiplimab, led to anti-tumor responses in patients with microsatellite stable colorectal cancer based on data from the dose-escalation portion of an ongoing phase 1/2 trial. Efficacy results from 51 patients with microsatellite stable colorectal cancer showed a...
Concord Acquisition to Transfer Securities to NYSE American
Concord Acquisition to Transfer Securities to NYSE American
May 23, 2024
05:32 PM EDT, 05/23/2024 (MT Newswires) -- Concord Acquisition Corp II ( CNDA ) will transfer its the listing of class A common stock, units and warrants to NYSE American, begin May 29 under the same ticker symbols of CNDA, CNDA.U and CNDA.WS, respectively. The company said Thursday the securities will continue trading on the New York Stock Exchange until...
Copyright 2023-2026 - www.financetom.com All Rights Reserved